Columbus Circle Investors’s Juno Therapeutics, Inc. JUNO Stock Holding History

Columbus Circle Investors’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-140,663	Closed	-$4.22M	–	330
2016 Q3	$4.22M	Buy	+140,663	New	+$4.38M	0.05%	213
2015 Q2	–	Sell	-232,031	Closed	-$14.1M	–	325
2015 Q1	$14.1M	Buy	232,031 +76,189	+49%	+$3.7M	0.1%	184
2014 Q4	$8.14M	Buy	+155,842	New	+$6.97M	0.06%	219

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Columbus Circle Investors's JUNO Position: Q4 2016 in Review

Columbus Circle Investors sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2016, closing a stake of 140,663 shares — an estimated $4.22M sold.

Columbus Circle Investors first reported a position in JUNO in Q4 2014 and held it in 3 quarters. The position peaked at $14.1M in Q1 2015. 159 funds tracked by Wall St. Rank hold JUNO as of Q4 2016.

Columbus Circle Investors reported no remaining Juno Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
Columbus Circle Investors sold 140,663 Juno Therapeutics, Inc. shares in Q4 2016, an estimated $4.22M.
Columbus Circle Investors first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 3 quarters.
Columbus Circle Investors's Juno Therapeutics, Inc. position peaked at $14.1M in Q1 2015.
159 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2016.

Based on Columbus Circle Investors's 13F filing for Q4 2016, filed 2 Feb 2017.